



Gritstone to Participate in Two Upcoming Investor Conferences

September 1, 2022

EMERYVILLE, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that management will present at the 2022 Wells Fargo Healthcare Conference, taking place September 7-9, 2022, in Boston, MA, and participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12-14, 2022, in New York, NY. The events will also be available via webcast. Please find additional details about the events below.

2022 Wells Fargo Healthcare Conference

Presentation Date: Thursday, September 8, 2022, 1:20pm EDT

Presenters: Celia Economides, Chief Financial Officer and Matthew J. Hawryluk, Chief Business Officer

Location: Boston, MA

Webcast: https://cc.webcasts.com/well001/090722a_js/?entity=91_L3I6VXR

H.C. Wainwright 24th Annual Global Investment Conference

Fireside Chat Date: Tuesday, September 13, 2022, 3:30pm EDT

Participant: Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer

Location: New York, NY

Webcast: <https://journey.ct/events/view/89b3603e-34a8-4be4-a1ae-12b3f8b4b14e>

The events will be accessible via the Investors & Media section of the company's website at <https://ir.gritstonebio.com/investors/events>. Archived replays will be accessible for 30 days following the events.

About Gritstone bio

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to develop the world's most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com

Gritstone Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone's therapeutic programs; the advancements in Gritstone's ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone's programs' clinical stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gritstone in general, see Gritstone's most recent Quarterly Report on Form 10-Q filed on August 4, 2022 and Gritstone's future reports to be filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Gritstone as of the date hereof. Gritstone disclaims any obligation to update any forward-looking statements, except as required by law.

Gritstone Contacts

Investors:

George E. MacDougall

Director, Investor Relations & Corporate Communications

Gritstone bio, Inc.

ir@gritstone.com

Media:

Dan Budwick

1AB

(973) 271-6085

dan@1abmedia.com

